- Issuer ticker
-
REGN
- Reported as of
-
08 Dec 2023
- Net transaction value
-
-$3,573,573
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
12 Dec 2023, 16:01:38 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/**Robert E. Landry
Key filing fact
Robert E. Landry filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 12 Dec 2023.
Key facts
- This page summarizes Robert E. Landry's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Dec 2023, 16:01.
Change
- Previous filing in this sequence was filed on 25 Aug 2023.
- Current net transaction value: -$3,573,573.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
REGN
transaction
Common Stock
Tax liability
- Transaction value
- $854,759
- Shares
- -1,013
- Change %
- -3.2%
- Price
-
$843.79
- Shares after
- 30,686
- Date
- 08 Dec 2023
- Ownership
- Direct
REGN
transaction
Common Stock
Tax liability
- Transaction value
- $564,696
- Shares
- -669
- Change %
- -2.2%
- Price
-
$844.09
- Shares after
- 30,017
- Date
- 11 Dec 2023
- Ownership
- Direct
REGN
transaction
Common Stock
Tax liability
- Transaction value
- $2,154,118
- Shares
- -2,552
- Change %
- -8.5%
- Price
-
$844.09
- Shares after
- 27,465
- Date
- 11 Dec 2023
- Ownership
- Direct
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
-
- Shares after
- 270
- Date
- 08 Dec 2023
- Ownership
- By 401(k) Plan
* marks a reported price that did not pass the local price check.